The self-reported health and productivity burden of autoimmune disorders at a major self-insured employer

Journal of Occupational and Environmental Medicine

Volumn 54, Issue 9, 2012, Pages 1049-1063

  Allen, Harris ^a   Bunn, William B ^a   Naim, Ahmad B ^a  

^a Harris Allen Group LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOIMMUNE DISEASE; DISEASE SEVERITY; EMPLOYER; ENTERITIS; FEMALE; HEALTH; HUMAN; MALE; PREVALENCE; PRODUCTIVITY; PSORIASIS; RHEUMATOID ARTHRITIS; SELF REPORT;

ADULT; ARTHRITIS, RHEUMATOID; CHICAGO; COST OF ILLNESS; EFFICIENCY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; OCCUPATIONAL HEALTH; ORGANIZATIONAL CASE STUDIES; PSORIASIS; SELF REPORT; UNITED STATES;

EID: 84866423740     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3182602447     Document Type: Article

References (64)

1. Bunn W, Stave G, Allen H, Naim A. Evidence-based benefit design: Toward a sustainable healthcare future for employers. J Occup Environ Med. 2010;52:951-955.
2. Bunn W, Allen H, Stave G, Naim A. How to align evidence-based benefit design with the employer bottom-line: A case study. J Occup Environ Med. 2010;52:956-963.
3. Goetzel R, Long S, Ozminkowski R. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. 2004;46:398-412.
4. Collins J,BaaseC, ShardaC, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med. 2005;47:547-557.
5. Loeppke R, Taitel M, Haufle V, et al. Health and productivity as a business strategy: A multi-employer study. J Occup Environ Med. 2009;51:411-428.
6. Burton W, Conti D, Chen C, Schultz AB, Edington DW. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med. 2001;43:64-71.
7. Weiss K, Sullivan S. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immun. 2001;107: 3
8. Stewart W, Ricci J, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA. 2003;289:3135-3144.
9. Wang P, Simon G, Avorn J, et al. Telephone screening, outreach and caremanagement for depressed workers and impact on clinical and work productivity outcomes, a randomized controlled trial. JAMA. 2007;298:1401-11.
10. Allen H, Rogers W, Bunn WB. Managing the burden of chronic obstructive pulmonary disease on workforce health and productivity: Upping a leading employer's game. J Occup Environ Health. 2012;54:1064-1077.
11. Bunn W, Pikelny D, Paralkar S, Slavin T, Borden S IV, Allen HM Jr. The burden of allergies - and the capacity of medications to reduce this burden - in a heavy manufacturing environment. J Occup Environ Med. 2003;45:941- 955.
12. AllenH, Borden S, Pikelny D, Paralkar S, Slavin T, BunnWBIII. An intervention to promote appropriate management of allergies in a heavymanufacturing setting: An evaluation of health and productivity outcomes. J Occup Environ Med. 2003,45:956-983.
13. Allen H, Bunn W. Validating self-reported measures of productivity at work: A case for their credibility in a heavy manufacturing setting. J Occup Environ Med. 2003,45:926-940.
14. Allen H, Bunn W. Using self-report and adverse event measures to track health's impact on productivity in known groups. J Occup Environ Med. 2003,45:973-983.
15. Allen H, Slavin T, Bunn W. Do long workhours impact health, safety and productivity at a heavy manufacturer? J Occup Environ Med. 2007;49:148- 171.
16. Allen H, Woock C, Barrington L, Bunn W. Age, overtime and employee health, safety and productivity outcomes: A case study. J Occup Environ Med. 2008;50:873-94.
17. Williams J, Meyers J. Immune-mediated inflammatory disorders (I.M.I.D.s): The economic and clinical costs. Am J Manag Care. 2002;8:S664-S681.
18. Tomankova T, Petrek M, Gallo J, Kriegova E. MicroRNAs: Emerging regulators of immune-mediated diseases. Scand J Immunol. 2011;75:129-141.
19. Vogenberg F, Holland J, Liebeskind D. Employer benefit design considerations for the era of biotech drugs. J Occup Environ Med. 2007;49:626- 632.
20. WebMD, Rheumatoid Arthritis (search article). Available at: Http://www. medicinenet.com/rheumatoid arthritis/article.htm. Published 2009.
21. HelmickC, FelsonD, LawrenceR, et al. Estimates of the prevalence of arthritis & other rheumatic conditions in the US. Arth Rheum. 2008;58:15-25.
22. Centers for Disease Control and Prevention. Prevalence of disabilities and associated health conditions among adults. United States, 1999.MMWRMorb Mortal Wkly Rep. 2001;50:120-125.
23. Stoddard S, Jans L, Ripple J, Kraus AL. Chart Book on Work and Disability in the US: An InfoUse Report. Washington, DC: US National Institute on Disability and Rehabilitation Research; 1998. Grant H133D50017-96.
24. Hootman J,Helmick C, Schappert S. Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory medical care visits. United States 1997. Arth Rheum. 2002;47:571-558.
25. Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short term disability benefits. J Occup Environ Med. 2006;48:135-148.
26. Kessler RC, Maclean JR, Petukhova M, et al. The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples. J Occup Environ Med. 2008;50:88-98.
27. Cole J, Li T, MacLean R,Wallenstein G. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: Re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. Rheumatology. 2008;47:1044-1050.
28. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev Dermatol. 2006;1:63-75.
29. Naldi L. The epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-128.
30. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Questions and answers about psoriasis. Available at: Http://www.niams.nih. gov.proxy1.lib.tju.edu:2048/Health Info/Psoriasis/. Accessed December 18, 2007.
31. Javitz H, Ward M, Farber E, Nail L, Vallow S. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-860.
32. Schmitt J, Ford D. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213:102-110.
33. Fowler J, Duh M, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59:772-780.
34. WebMD, Inflammatory bowel disease (search article). Available at: Http:// www.medterms.com/script/main/art.asp?articlekey=7540. Published 2009.
35. Karlinger K, Gyorke T, Mako E, Mester A, Tarjan Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol. 2000;35:154- 167.
36. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417- 429.
37. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504- 1517.
38. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct healthcare costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
39. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease & ulcerative colitis. J Occup Environ Med. 2008;50:1261- 1272.
40. Ware J. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
41. Health Management Research Center. Edington's Research Slides.Ann Arbor: University of Michigan; 2010. Available at: Www.hmrc.umich.edu.
42. Stewart A, Ware J. eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992.
43. Rogers W, Wilson I, Bungay KM, Cynn DJ, Adler DA. Assessing the performance of a new depression screener for primary care. J Clin Epidemiol. 2002;55:164-175.
44. Employers Health Coalition. The Hidden Competitive Edge: Employee Health and Productivity. Tampa, FL: Employers Health Coalition; 2000.
45. Stenton C. The MRC Breathlessness Scale. Occup Med. 2008;58:226- 227.
46. Kessler RC, Barber C, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire. J Occup Environ Med. 2003;45:156- 174.
47. Tepas D, Monk T. Work schedules. In: Salvendy G, ed. Handbook of Human Factors. New York: John Wiley & Sons; 1987:819-843.
48. Allen H. The Health and Work Productivity - One Survey. Brookline, MA: Harris Allen Group; 2007.
49. Lerner D, Amick B III, Rogers WH, Malspeis S, Bungay K, Cynn D. Work Limitations Questionnaire. Med Care. 2001;39:72-85.
50. Shain M. Stress and satisfaction: The role of occupational health and safety. Occup Health Saf Can. 1999;15:38-47.
51. Industrial Accident Prevention Association. The Stress & Satisfaction Offset Scale Score (SSOS): A Self Assessment. Mississauga, Ontario, Canada: Industrial Accident Prevention Association; 2008.
52. Gibbons J. Finding a Definition of Employee Engagement. Executive Action Reports. New York: The Conference Board (report # A-0236-07-EA); 2007.
53. Gibbons J. Employee Engagement A Review of Current Research and Its Implications. Ottawa, Ontario, Canada: The Conference Board; 2006.
54. Ware J, Kosinski M, Keller S. A 12-Item Short-Form Health Survey. Med Care. 1996;34:220-223.
55. Rogers W, Oian S, Kazis L. Imputing the Physical and Mental Summary Scores for the MOS SF-36 and the Veterans SF-36 Health Survey in the Presence of Missing Data. Bedford,MA: Center forHealth Quality,Outcomes and Economic Research, Department of Veterans Affairs; 2004.
56. Allen H, Darling H, McNeill D, Bastien F. The employee health care value survey: Round one. Health Aff. 1994;13:26-41.
57. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preferencebased single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:1115-1128.
58. Roberta A, John B. Predicting the Short Form-6D Preference-Based Index using the eight mean short form-36 health dimension scores: Estimating preference-based health-related utilities when patient level data are not available. Value Health. 2009;12:346-353.
59. Lerner D, Rogers W, Chang H. Scoring the Work Limitations Questionnaire (WLQ) Scales and the WLQ Index for Estimating Work Productivity Loss. Boston, MA: ICRHPS, Tufts Medical Center; 2003:1-9.
60. Campbell D, Fiske D. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull. 1959;56:81-105.
61. Navistar Health Benefits Department. Description of Plan Benefits. Lisle, IL: Navistar; 2008.
62. Lipsky P, Van Del Heijde D, St Clair E, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343:1594-1602.
63. Targan S, Hanauer S, van Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor A for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
64. Schopf R, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor A, infliximab. J Am Acad Dermatol. 2002; 46:886-891.